Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
  • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/275—Nitriles; Isonitriles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
  • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics

Definitions

• the invention relates to novel cyclodextrin inclusion complexes, process for their preparation and their use,
• the present invention relates to inclusion complexes of the compound 4-[3-[ ethyl[3-(propylsulfinyl)-propyl]amino]-2-hydroxypropoxy]-benzonitrile with cyclodextrins, their preparation and use.
• the present invention relates to an inclusion complex of the compound of the formula I with one or more cyclodextrins.
• the compound of the formula I is present in the form of a stereoisomeric mixture.
• the compound of the formula I is present in the form of one of the stereoisomers.
• stereoisomers are, in addition to the two stereoisomers mentioned above, the following: 4-[3-[ethyl[3-((R*)-propylsulfinyl)propyl]amino]-2(R)- hydroxypropoxy]-benzonitrile,
• the cyclodextrin may be an unsubstituted cyclodextrin, i.e. ⁇ -, ⁇ - or ⁇ -cyclodextrin, or a substituted cyclodextrin, e.g.
• a substituted cyclodextrin selected from the group consisting of methylcyclodextrins, ethylcyclodextrins, hydroxyethyl cyclodextrins and hydroxypropyl cyclodextrins.
• hydroxyethyl and hydroxypropyl cyclodextrins are hydroxyethyl- ⁇ -cyclodextrin and hydroxypropyl- ⁇ - cyclodextrin, respectively.
• the cyclodextrin is ⁇ -cyclodextrin or ⁇ - cyclodextrin.
• the inclusion complex may be formed with one single cyclodextrin or with a mixture of at least two cyclodextrins such as those mentioned above.
• the molar ratio between the cyclodextrin or mixture of cyclodextrins and the compound of the. formula I will generally be in the range of from 10:1 to 1:10, preferably above or equal to 1:1, such as 1:1 to 5:1.
• the present invention also relates to a process for the preparation of an inclusion complex according to the present invention, which process comprises reacting the compound of the formula I above with a cyclodextrin or a mixture of cyclodextrins.
• the reaction is typically carried out in a suitable solvent such as water.
• the invention further relates to a method of preventing or reducing cardiac arrhythmias in mammals, including man, which comprises administering to a host in need of such treatment an effective amount of an inclusion complex of the compound of the formula I with one or more cyclodextrins.
• the invention yet further relates to an inclusion complex of the compound of the formula I with one or more cyclodextrins for use as a medicament, particularly as an antiarrhythmic agent.
• the invention also relates to the use of an inclusion complex of the compound of the formula I with one or more cyclodextrins for the manufacture of medicaments with action against cardiac arrhythmias.
• Solution 1 was prepared by dissolving 7.53 g 4-[3-[ethyl[3-(propylsulfinyl)propyl]amino]-2-hydroxypropoxy]-benzonitrile, 1.54 g tartaric acid in 5 g deionized water.
• Solution 2 was prepared by dissolving 43.0 g ⁇ -cyclodextrin in 300 g deionized water by agitation at 70°C.
• Solution 1 was prepared by dissolving 0.75 g 4-[3-[ethyl-[3-(propylsulfinyl)propyl]amino]-2-hydroxypropoxy]-benzonitrile, 0.153 g tartaric acid in 2.5 g deionized water.
• Solution 2 was prepared by dissolving 4.3 g ⁇ -cyclodextrin in 30 g water at 25°C.
• Solution 1 was poured
• the total yield was 4 g and the content 4-[3-/ethyl[3-(propylsulfinyl)propyl]amino]-2-hydroxypropoxy]-benzonitrile was assayed spectrophotometrically to 15 % by weight.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Nanotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Crystallography & Structural Chemistry (AREA)
• Biotechnology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Medical Informatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biophysics (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=20376340

Family Applications (1)

Country Status (15)

Families Citing this family (5)

Family Cites Families (10)

• 1989
  • 1989-06-20 SE SE8902235A patent/SE8902235D0/xx unknown
• 1990
  • 1990-06-15 IE IE216290A patent/IE902162A1/en unknown
  • 1990-06-16 DD DD90341729A patent/DD297404A5/de not_active IP Right Cessation
  • 1990-06-18 GR GR900100458A patent/GR1000747B/el unknown
  • 1990-06-19 HU HU905542A patent/HUT59085A/hu unknown
  • 1990-06-19 WO PCT/SE1990/000436 patent/WO1990015792A1/en not_active Application Discontinuation
  • 1990-06-19 KR KR1019910701912A patent/KR920702674A/ko not_active Application Discontinuation
  • 1990-06-19 AU AU59374/90A patent/AU641670B2/en not_active Ceased
  • 1990-06-19 EP EP90910159A patent/EP0478677A1/en not_active Ceased
  • 1990-06-19 CA CA002058996A patent/CA2058996A1/en not_active Abandoned
  • 1990-06-19 JP JP2509477A patent/JPH04506212A/ja active Pending
  • 1990-06-19 PT PT94415A patent/PT94415A/pt not_active Application Discontinuation
• 1991
  • 1991-12-17 FI FI915935A patent/FI915935A0/fi not_active Application Discontinuation
• 1993
  • 1993-06-30 LV LV930886A patent/LV10249A/xx unknown
  • 1993-12-30 LT LTIP1725A patent/LTIP1725A/xx not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events